Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
作者信息
Levine Glenn N, D'Amico Anthony V, Berger Peter, Clark Peter E, Eckel Robert H, Keating Nancy L, Milani Richard V, Sagalowsky Arthur I, Smith Matthew R, Zakai Neil
出版信息
Circulation. 2010 Feb 16;121(6):833-40. doi: 10.1161/CIRCULATIONAHA.109.192695. Epub 2010 Feb 1.
Abstract
摘要
相似文献
1
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
Circulation. 2010 Feb 16;121(6):833-40. doi: 10.1161/CIRCULATIONAHA.109.192695. Epub 2010 Feb 1.
2
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
CA Cancer J Clin. 2010 May-Jun;60(3):194-201. doi: 10.3322/caac.20061. Epub 2010 Feb 2.
3
Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.
Drugs. 2011 Feb 12;71(3):255-61. doi: 10.2165/11588930-000000000-00000.
4
Long term androgen deprivation therapy in prostate cancer.
BMJ. 2008 Sep 22;337:a1361. doi: 10.1136/bmj.a1361.
5
Androgen deprivation therapy and cardiovascular risk.
Practitioner. 2015 Sep;259(1785):5.
6
Androgen deprivation therapy and cardiovascular complications.
Bratisl Lek Listy. 2016;117(10):557-561. doi: 10.4149/BLL_2016_109.
7
[Cardiovascular risks of androgen deprivation therapy for prostate cancer].
Urologe A. 2016 May;55(5):627-31. doi: 10.1007/s00120-015-0021-1.
8
Androgen deprivation therapy for prostate cancer.
J Urol. 2007 Oct;178(4 Pt 1):1148. doi: 10.1016/j.juro.2007.07.066. Epub 2007 Aug 14.
9
Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
Curr Urol Rep. 2017 Jun;18(6):41. doi: 10.1007/s11934-017-0688-5.
10
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54. doi: 10.1097/MED.0b013e32814db88c.
引用本文的文献
1
Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.
Prostate. 2025 Sep;85(12):1077-1086. doi: 10.1002/pros.24913. Epub 2025 Jun 11.
2
Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study.
Clin Transl Radiat Oncol. 2025 Mar 10;52:100944. doi: 10.1016/j.ctro.2025.100944. eCollection 2025 May.
3
Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer.
Cardiooncology. 2025 Mar 29;11(1):31. doi: 10.1186/s40959-025-00318-5.
4
Disparities in Cancer and Cardiovascular Disease Mortality Among Asian Americans Diagnosed with Urologic Cancer.
J Racial Ethn Health Disparities. 2025 Mar 11. doi: 10.1007/s40615-025-02354-4.
5
Assessing the effects of prostate cancer therapies on cardiovascular health.
Nat Rev Urol. 2025 Feb 26. doi: 10.1038/s41585-025-01002-0.
6
Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer.
Cardiooncology. 2024 Dec 5;10(1):87. doi: 10.1186/s40959-024-00278-2.
7
The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.
Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727.
8
Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies.
Prostate Cancer Prostatic Dis. 2024 Nov 6. doi: 10.1038/s41391-024-00897-x.
9
A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer.
Clin Transl Oncol. 2025 Jun;27(6):2679-2688. doi: 10.1007/s12094-024-03772-2. Epub 2024 Nov 5.
10
Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer.
Steroids. 2024 Oct;210:109482. doi: 10.1016/j.steroids.2024.109482. Epub 2024 Jul 23.
本文引用的文献
1
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
JAMA. 2009 Aug 26;302(8):866-73. doi: 10.1001/jama.2009.1137.
2
Duration of androgen suppression in the treatment of prostate cancer.
N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.
3
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
J Clin Oncol. 2009 Jul 20;27(21):3452-8. doi: 10.1200/JCO.2008.20.0923. Epub 2009 Jun 8.
4
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.
J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.
5
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.
Cancer. 2008 Dec 15;113(12):3290-7. doi: 10.1002/cncr.23970.
6
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.
7
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.
8
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
Urology. 2008 Feb;71(2):318-22. doi: 10.1016/j.urology.2007.08.035.
9
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Eur Urol. 2008 Oct;54(4):816-23. doi: 10.1016/j.eururo.2008.01.021. Epub 2008 Jan 15.
10
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
JAMA. 2008 Jan 23;299(3):289-95. doi: 10.1001/jama.299.3.289.
Zotero 插件